Oren G. Livnat

Amid a flood of news from smaller bio-pharmaceutical concerns, analysts at JMP Securities picked through some winners and losers. The firm's analysts maintained Outperform ratings Wednesday on Infinity Pharmaceuticals Inc. (NASDAQ: INFI), Impax Laboratories Inc (NASDAQ: IPXL) and...

Following Valeant Pharmaceutical’s (NYSE: VRX) Acquisition of Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP), analysts at JMP Securities offered commentary on the deal. Within the note, Oren Livnat wrote, “Salix Pharmaceuticals has agreed to be acquired by Valeant for ~$14.5B cash...

Achillion Pharmaceuticals Inc.'s (NASDAQ: ACHN) recent interim data for its developmental hepatitis C drug is "incrementally positive," according to JMP Securities' Liisa A. Bayko. Achillion's Monday data dump is among a half-dozen drug company developments that JMP analysts commented on Tuesday....

In a report published Tuesday, JMP Securities analyst Oren G. Livnat initiated coverage on Pernix Therapeutics Holdings Inc (NASDAQ: PTX) with a Market Outperform rating and $13.00 price target. In the report, JMP Securities noted, “We are initiating coverage of Pernix Therapeutics with a Market...

Salix Pharmaceutical's (NASDAQ: SLXP) $2.7 billion inversion deal disappointed investors Wednesday who complain it dilutes near-term earnings and makes Salix seem like an unlikely merger candidate any time soon. Salix said after the bell Tuesday it will acquire the Irish unit of Italy's...

In a report published Wednesday, Jefferies analyst Oren G. Livnat reiterated a Hold rating on Actavis PLC (NYSE: ACT), and raised the price target from $133.00 to $168.00. In the report, Jefferies noted, “ACT delivered in-line Q3 and solid 1st-time ‘14 guide w/ WCRX that looks conservative. ACT...

In a report published Tuesday, Jefferies analyst Oren G. Livnat reiterated a Buy rating on AcelRx Pharmaceuticals (NASDAQ: ACRX), and raised the price target from $13.00 to $14.00. In the report, Jefferies noted, “All previously laid out timelines hold and numerous potential catalysts lie ahead...

In a report published Tuesday, Jefferies analyst Oren G. Livnat reiterated a Buy rating on Vanda Pharmaceuticals (NASDAQ: VNDA), and raised the price target from $11.00 to $13.00. In the report, Jefferies noted, “FDA accepted the Tasimelteon NDA, granted priority review (8-month review, Jan 31...

In a report published Tuesday, Jefferies analyst Oren G. Livnat downgraded Elan (NYSE: ELN) from Buy to Hold, and lowered the price target from $19.00 to $16.50. In the report, Jefferies noted, “ELN agreed to be acquired by Perrigo for ~$8.6B or $16.50/shr (based on prior PRGO stock price), a...

In a report published on Monday, Jefferies analyst Oren G. Livnat downgraded Elan Corp (NYSE: ELN) from Buy to Hold and lowered the price target on the company from $19 to $15. In the report, Jefferies stated, "LN agreed to be acquired by Perrigo for ~$8.6B or $16.50/shr (based on prior PRGO...

Jefferies & Company analysts Corey Davis, Graig Suvannavejh and Oren G. Livnat maintained their Buy rating for shares of Endo Pharmaceuticals (NASDAQ: ENDP), with a price target of $26 per share. The analysts wrote that after announcing plans to acquire HealthTronics Inc. (NASDAQ: HTRN) for $...